## CDC73 (A264) Antibody Image: Cell Signaling Tech Nology Orders: 877-616-CELL (2355) orders@cellsignal.com Support: 877-678-TECH (8324) Web: info@cellsignal.com cellsignal.com



3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W, IP	<b>Reactivity:</b> H M R Mk	<b>Sensitivity:</b> Endogenous	<b>MW (kDa):</b> 60	<b>Source/Isotype:</b> Rabbit	UniProt ID: #Q6P1J9	Entrez-Gene Id: 79577
Product Usage Information	e	<b>Application</b> Western Blotting Immunoprecipitation			<b>Dilution</b> 1:1000 1:50	
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA and 50% glycerol. Store at – 20°C. Do not aliquot the antibody.				
Specificity/Sensitivity		CDC73 (A264) Antibody detects endogenous levels of total CDC73 protein.				
Source / Purification		Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala264 of human CDC73. Antibodies are purified by peptide affinity chromatography.				
Background		CDC73 (HPRT2) is a putative tumor suppressor protein thought to bind RNA polymerase II to help inhibit cell cycle progression (1,2). Commonly referred to as parafibromin, CDC73 is expressed in endocrine tissues, kidney, heart, and skeletal muscle and is localized to both nuclear and cytoplasmic compartments (3). CDC73 acts as a Wnt signaling regulator as it binds the carboxy-terminal region of $\beta$ - catenin (4). Mutations in the corresponding gene cause an endocrine disorder known as hyperparathyroidism 2, which is characterized by hypercalcemia, bone resorption, and the development of jaw tumors (5).				
Background References		1. Rozenblatt-Rosen, O. et al. (2005) <i>Mol Cell Biol</i> 25, 612-20. 2. Shi, X. et al. (1997) <i>Mol Cell Biol</i> 17, 1160-9. 3. Woodard, G.E. et al. (2005) <i>Oncogene</i> 24, 1272-6. 4. Mosimann, C. et al. (2006) <i>Cell</i> 125, 327-41. 5. Bradley, K.J. et al. (2006) <i>Clin Endocrinol (Oxf)</i> 64, 299-306.				
Species Reacti	ivity	Species reactivity is de	termined by testing	g in at least one approve	ed application (e.g.,	western blot).
Western Blot Buffer		IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.				
Applications Key		W: Western Blotting IP: Immunoprecipitation				
Cross-Reactivity Key		H: Human M: Mouse R: Rat Mk: Monkey				
Trademarks and Patents		Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.				
		All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.				
Limited Uses		Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.				
		approved, cleared, or l purpose. Customer sh any manner that confl Customer as the end-u	icensed by the FDA all not use any Proo icts with its labeling user and solely for i	se Only or a similar labe or other regulatory for duct for any diagnostic o statement. Products so research and developme urposes, or any purchase	eign or domestic er or therapeutic purp old or licensed by C ent uses. Any use of	ntity, for any ose, or otherwise in ST are provided for f Product for

component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.